Fabric.AI taps Kearney to lead commercialization strategy for Neural I/o optical interconnect platform
Bitget2026/10/06 13:15Fabric.AI engaged Kearney to lead commercialization strategy for its Neural I/o MicroLED-based optical interconnect platform. Kearney will apply infrastructure and supply chain expertise to build a commercial pipeline, refine positioning, and prioritize customers. Active sales discussions are expected to start following planned working-hardware demonstrations in early 2027. The work builds on ongoing technical talks under NDAs with several semiconductor and data center technology companies. Fabric.AI is developing Neural I/o with Kopin as its development partner. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fabric.ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060915PRIMZONEFULLFEED9840239) on October 06, 2026, and is solely responsible for the information contained therein.
- Fabric.AI engaged Kearney to lead commercialization strategy for its Neural I/o MicroLED-based optical interconnect platform.
- Kearney will apply infrastructure and supply chain expertise to build a commercial pipeline, refine positioning, and prioritize customers.
- Active sales discussions are expected to start following planned working-hardware demonstrations in early 2027.
- The work builds on ongoing technical talks under NDAs with several semiconductor and data center technology companies.
- Fabric.AI is developing Neural I/o with Kopin as its development partner.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300